[Expert recommendations: Hepatitis C and transplantation].

Area of Science:

• Hepatology
• Virology
• Transplantation Medicine

Background:

• Direct-acting antiviral (DAA) agents have revolutionized hepatitis C virus (HCV) treatment.
• Limited data exist on optimal DAA strategies for patients undergoing or who have undergone liver transplantation (LT).

Purpose of the Study:

• To provide evidence-based recommendations for using DAAs in patients with HCV before and after LT.
• To guide clinical decision-making for managing HCV in the context of liver transplantation.

Main Methods:

• Review of current literature on DAA efficacy and safety in LT patients.
• Consensus discussion among experts in hepatology and transplantation.

Main Results:

• Interferon-free DAA regimens demonstrate high efficacy and favorable safety profiles.
• Treatment strategies for patients awaiting LT and those post-LT require further definition.

Conclusions:

• DAAs represent a significant advancement in managing HCV in LT candidates and recipients.
• Expert recommendations are crucial for navigating DAA therapy in this complex patient population.